Research Information Only — Educational content, not medical advice. Both are physician-managed; retatrutide is investigational. This is education, not a prescription.
PeptideReport.ai
Compare › Retatrutide vs Tirzepatide

Comparison · Metabolic

Retatrutide vs tirzepatide

The dual agonist everyone knows versus the triple agonist everyone’s watching. Retatrutide adds a third mechanism tirzepatide doesn’t have — and the honest question isn’t “which is stronger” but “which fits this person, given the stakes.” Here’s the head-to-head.

Dual vs Triple+ GlucagonInvestigationalMatch, Don’t Default

The Mechanisms

Two receptors vs three

Tirzepatide is a dual agonist: GLP-1 plus GIP. Retatrutide is a triple agonist: GLP-1, GIP, and glucagon. The first two actions overlap; the difference is retatrutide’s added glucagon-receptor activity, of interest for energy expenditure and metabolic effect. Each step up the class — single, dual, triple — adds a mechanism.

Tirzepatide

GLP-1 + GIP (dual). Established, widely used, large effect in trials versus single agonists.

vs
Retatrutide

GLP-1 + GIP + glucagon (triple). Investigational; the added glucagon action is the differentiator.

The Trials

More comprehensive, generally larger effect

In clinical trials, the more comprehensive multi-receptor agents have generally produced greater metabolic effect, and retatrutide has drawn attention for the magnitude of results reported. But bigger effect is not automatically better for a given person — it also raises the stakes on side effects, tolerability, and, critically, muscle preservation. And retatrutide remains investigational, where tirzepatide is established. See the retatrutide profile and semaglutide vs. tirzepatide.

The Selection

Match the person, not the headline

The deterministic logic doesn’t default to strongestIt matches the compound to the goal and history: the size of the weight-loss target, whether diabetes is the driver, tolerance, and the muscle-preservation plan. A triple agonist’s greater effect raises the stakes on all of those. So tirzepatide is the right answer for some people and retatrutide for others — a physician’s call against the whole picture, not a grab for the newest thing. See how a clinician chooses.

Shared Rules

Same fundamentals, higher stakes

You still can’t coast on the shotBoth carry the class’s GI effects and both demand titration, monitoring, and muscle preservation — protein and resistance training — more so as potency climbs. Research-grade material needs a certificate of analysis. And retatrutide’s investigational status is itself a reason for extra caution and oversight. See why you can’t coast on GLP-1.

Common Questions

Retatrutide vs tirzepatide, answered

What's the difference between retatrutide and tirzepatide?
Tirzepatide is a dual agonist (GLP-1 + GIP); retatrutide is a triple agonist that adds glucagon-receptor activity. The added glucagon action is the differentiator, of interest for energy expenditure.
Which causes more weight loss?
In trials, more comprehensive multi-receptor agents have generally shown larger effects, and retatrutide has drawn attention for its magnitude. But bigger effect isn't automatically right for a given person — it raises the stakes on side effects and muscle preservation.
Is retatrutide better than tirzepatide?
Not automatically. Retatrutide is investigational where tirzepatide is established, and the right choice depends on goal, history, tolerance, and the muscle-preservation plan — a physician's call, not 'newest wins.'
Do the same rules apply to both?
Yes — GI effects, titration, monitoring, and muscle preservation (protein + resistance training), more so as potency climbs. Both need a certificate of analysis, and retatrutide's investigational status warrants extra caution.

Brand Names

You may know these by their brand namesSemaglutide is sold as Ozempic and Wegovy (and oral Rybelsus); tirzepatide as Mounjaro and Zepbound.

Sources

Primary references for this page. Links open PubMed, ClinicalTrials.gov, FDA or regulator records.

  1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — N Engl J Med, 2023
  2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial — Lancet, 2023
  3. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — N Engl J Med, 2022
  4. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1, phase 3) — ClinicalTrials.gov, 2023

About the Author

SD
Dr. Scott DelBoccio, DMD
Founding Author · PeptideReport.ai

Dr. DelBoccio is a clinician with thirty years of practice and a focus on peptide pharmacology and metabolic health. PeptideReport.ai is the clinician-authored, education-only reference the peptide space lacked. No products are sold on this site.

Full Disclaimer

This page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The compounds discussed are research/investigational and require physician supervision. PeptideReport.ai does not manufacture, sell, or endorse any preparation. Content addresses adults 21 and older. Evidence and regulatory status continue to evolve.